Safety of stimulant treatment in attention deficit hyperactivity disorder: part I

被引:16
作者
Merkel, Richard Lawrence, Jr. [1 ]
Kuchibhatla, Ajay [1 ]
机构
[1] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA 22908 USA
关键词
adverse events; amphetamine; attention deficit hyperactivity disorder; dexmethylphenidate; dextroamphetamine; lisdexamfetamine dimesylate; methylphenidate; mixed amphetamine salts; psychostimulants; substance abuse and dependence; PLACEBO-CONTROLLED TRIAL; SALTS EXTENDED-RELEASE; LONG-ACTING STIMULANTS; DOUBLE-BLIND; DEFICIT/HYPERACTIVITY DISORDER; SUBSTANCE USE; PRESCHOOL-CHILDREN; OROS METHYLPHENIDATE; COLLEGE-STUDENTS; ILLICIT USE;
D O I
10.1517/14740330903279956
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The safety profile of newer stimulant products is of interest. Because most studies focus on school-age children, there is also an increased interest in the treatment of other populations. Concern continues for the risk of substance abuse in the use of stimulants. Objective: The purpose of this paper is to review published data on the safety and tolerability of the newer forms of stimulants, treatment in special populations, and the risks of substance abuse and dependence in the treatment of attention deficit hyperactivity disorder. Methods: Literature obtained through Medline and Pubmed from 1995 were reviewed as well as key articles referenced in the literature. Conclusions: The use of the newer stimulant agents shows a safety profile of frequent, but usually mild side effects. They are generally safe in special populations. The risk of developing long-term substance abuse with attention deficit hyperactivity disorder, without co-morbidities, is small and may decrease with proper treatment. More research is needed.
引用
收藏
页码:655 / 668
页数:14
相关论文
共 86 条
  • [1] Ahmann P. A., 1993, PEDIATRICS, V86, P184
  • [2] Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266
  • [3] A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder
    Arnold, LE
    Lindsay, RL
    Conners, CK
    Wigal, SB
    Levine, AJ
    Johnson, DE
    West, SA
    Sangal, RB
    Bohan, TP
    Zeldis, JB
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2004, 14 (04) : 542 - 554
  • [4] ARNOLD LE, 1978, ARCH GEN PSYCHIAT, V35, P463
  • [5] The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder
    Ashton, Heather
    Gallagher, Peter
    Moore, Brian
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2006, 20 (05) : 602 - 610
  • [6] BARKLEY RA, 1990, PEDIATRICS, V86, P184
  • [7] Barkley RA, 2002, J CLIN PSYCHIAT, V63, P10
  • [8] A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
    Biederman, J
    Mick, E
    Surman, C
    Doyle, R
    Hammerness, P
    Harpold, T
    Dunkel, S
    Dougherty, M
    Aleardi, M
    Spencer, T
    [J]. BIOLOGICAL PSYCHIATRY, 2006, 59 (09) : 829 - 835
  • [9] A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder
    Biederman, J
    Lopez, FA
    Boellner, SW
    Chandler, MC
    [J]. PEDIATRICS, 2002, 110 (02) : 258 - 266
  • [10] Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: A naturalistic controlled 10-year follow-up study
    Biederman, Joseph
    Monuteaux, Michael C.
    Spencer, Thomas
    Wilens, Timothy E.
    MacPherson, Heather A.
    Faraone, Stephen V.
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2008, 165 (05) : 597 - 603